The remaining study (Leskelä et al., 2011), in 118 Spanish paclitaxel-treated cancer patients reported a protective association for CYP3A5*3 (p = 0.012, hazard ratio per allele = 0.51, 95% CI = 0.30–0.86). This evidence concerns the gene CYP3A5 and cancer.